Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» XenoPort to continue development of XP23829 after Phase 1 results
XenoPort to continue development of XP23829 after Phase 1 results
XenoPort to continue development of XP23829 after Phase 1 results
Submitted by
admin
on September 9, 2013 - 5:18pm
Source:
Yahoo/Fly on the Wall
News Tags:
XenoPort
XP23829
psoriasis
multiple sclerosis
Headline:
XenoPort to continue development of XP23829 after Phase 1 results
Do Not Allow Advertisers to Use My Personal information
